Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Return on Equity (2018 - 2025)

Historic Return on Equity for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Q3 2025 value amounting to 0.38%.

  • Crinetics Pharmaceuticals' Return on Equity fell 500.0% to 0.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.38%, marking a year-over-year decrease of 500.0%. This contributed to the annual value of 0.32% for FY2024, which is 1700.0% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Return on Equity of 0.38% as of Q3 2025, which was down 500.0% from 0.3% recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Return on Equity's 5-year high stood at 0.25% during Q1 2025, with a 5-year trough of 0.69% in Q2 2023.
  • Moreover, its 5-year median value for Return on Equity was 0.37% (2021), whereas its average is 0.39%.
  • In the last 5 years, Crinetics Pharmaceuticals' Return on Equity crashed by -3000bps in 2023 and then skyrocketed by 3900bps in 2024.
  • Over the past 5 years, Crinetics Pharmaceuticals' Return on Equity (Quarter) stood at 0.31% in 2021, then crashed by -58bps to 0.49% in 2022, then rose by 21bps to 0.38% in 2023, then grew by 28bps to 0.28% in 2024, then tumbled by -37bps to 0.38% in 2025.
  • Its Return on Equity stands at 0.38% for Q3 2025, versus 0.3% for Q2 2025 and 0.25% for Q1 2025.